AAV-based treatment of cholesterol-related disorders
The invention in some aspects relates to methods and compositions for assessing the effectiveness of miRNA inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided. In one aspect of the invention, miRNA inhibitors against miR-122 and rAAV-based compositions comprising the same are provided.
1. A method for reducing serum cholesterol in a subject, the method comprising:
administering an effective amount of a recombinant Adeno-Associated Virus (rAAV) to the subject, wherein the rAAV comprises at least one transgene that expresses a miRNA inhibitor that inhibits the expression of miR-122 in the subject, and wherein the miRNA inhibitor comprises or consists of a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 21, or SEQ ID NO: 23.
2. The method of claim 1 , wherein the miRNA inhibitor comprises a miR-122 binding site.
3. The method of claim 2 , wherein the miR-122 binding site is flanked by two stem sequences.
4. The method of claim 2 , wherein the miR-122 binding site comprises a non-binding, central portion that is not complementary with miR-122, flanked by two portions that are complementary with miR-122.
5. The method of claim 1 , wherein the miRNA inhibitor comprises a first miR-122 binding site and a second miR-122 binding site, wherein a first stem sequence flanks the first miR-122 binding site at its 5′-end, a second stem sequence flanks the first miR-122 binding site at its 3′-end and the second miR-122 binding site at its 5′-end, and a third stem sequence flanks the second miR-122 binding site at its 3′-end.
6. The method of claim 5 , wherein each of the two miR-122 inhibitor binding sites comprises a non-binding, central portion that is not complementary with miR-122.
7. The method of claim 6 , wherein the non-binding, central portion of the first miR-122 binding site is at least partially complementary with the non-binding, central portion of the second miR-122 binding site.
8. The method of claim 6 , wherein the non-binding, central portion of the first miR-122 binding site has a length in a range of 1 to 10 nucleotides.
9. The method of claim 6 , wherein the non-binding, central portion of the second miR-122 binding site has a length in a range of 1 to 10 nucleotides.
10. The method of claim 1 , wherein the miRNA inhibitor comprises two or more miR-122 binding sites.
11. The method of claim 1 , wherein the rAAV has a capsid of the AAV9 serotype, which has a sequence as set forth in SEQ ID NO: 3.
12. The method of claim 1 , wherein the rAAV has a capsid of the AAV9 serotype variant, Csp-3, which has a sequence as set forth in SEQ ID NO: 4.
13. The method of claim 1 , wherein the serum cholesterol is total serum cholesterol, high density lipoprotein (HDL) cholesterol, and/or low density lipoprotein (LDL) cholesterol.
14. The method of claim 1 , wherein the rAAV targets liver tissue.
15. The method of claim 1 , wherein the rAAV transduces hepatocytes.
16. The method of claim 1 , wherein administering is performed intravenously.
17. The method according to claim 1 , wherein the subject is characterized by a total serum cholesterol level greater than or equal to 200 mg/dl.
18. The method of claim 13 , wherein the serum cholesterol is HDL cholesterol, optionally wherein administration of the rAAV results in reduction of HDL cholesterol levels in the subject 10 weeks post-administration.
19. The method of claim 13 , wherein the serum cholesterol is LDL cholesterol, optionally wherein administration of the rAAV results in reduction of LDL cholesterol levels in the subject 10 weeks post-administration.